Neos Therapeutics missed Q2 EPS and revenue estimates. Higher-than-expected costs drove the share price to new 52-week lows. Adzenys launch trending ahead of my expectations. The company said that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback